Literature DB >> 17309705

Epidemiology of refractory neuropathic pain.

Rod S Taylor1.   

Abstract

Although neuropathic pain can be acute in nature, in most patients the pain is persistent (or "refractory"). Patients with chronic neuropathic pain are seen most often in clinical practice. It consists of a number of different disease-specific indications, each of which can have differing diagnostic definitions and cutoffs. Consequently, it is difficult to estimate precisely the prevalence and incidence of neuropathic pain. The limited currently available epidemiological literature is reviewed in this article. The burden of neuropathic pain on patients and healthcare systems appears to be potentially large, with an estimated prevalence of 1.5%. Patients with neuropathic pain experience a poor health-related quality of life and consume a high level of healthcare resources, and costs. The future prioritization by healthcare policy makers for neuropathic pain treatment funding requires further data to clarify its epidemiology, the burden on the health of patients, and the demand on healthcare budgets.

Entities:  

Mesh:

Year:  2006        PMID: 17309705     DOI: 10.1111/j.1533-2500.2006.00054.x

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  28 in total

1.  Failed back surgery syndrome - definition, epidemiology and demographics.

Authors:  Simon Thomson
Journal:  Br J Pain       Date:  2013-02

2.  Diagnosis and treatment of failed back surgery syndrome in the UK: mapping of practice using a cross-sectional survey.

Authors:  Puvan Tharmanathan; Joy Adamson; Rebecca Ashby; Sam Eldabe
Journal:  Br J Pain       Date:  2012-11

3.  Analgesic properties of a peripherally acting and GalR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models.

Authors:  Cameron S Metcalf; Brian D Klein; Daniel R McDougle; Liuyin Zhang; Misty D Smith; Grzegorz Bulaj; H Steve White
Journal:  J Pharmacol Exp Ther       Date:  2014-10-27       Impact factor: 4.030

4.  Relationship of axonal voltage-gated sodium channel 1.8 (NaV1.8) mRNA accumulation to sciatic nerve injury-induced painful neuropathy in rats.

Authors:  Supanigar Ruangsri; Audrey Lin; Yatendra Mulpuri; Kyung Lee; Igor Spigelman; Ichiro Nishimura
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

Review 5.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

6.  Evaluation of quality of life and neuropathic pain in patients with low back pain using the Japanese Orthopedic Association Back Pain Evaluation Questionnaire.

Authors:  Akihiko Hiyama; Masahiko Watanabe; Hiroyuki Katoh; Masato Sato; Daisuke Sakai; Joji Mochida
Journal:  Eur Spine J       Date:  2014-12-14       Impact factor: 3.134

7.  Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain.

Authors:  Lisa C Loram; Jacqueline A Harrison; Evan M Sloane; Mark R Hutchinson; Paige Sholar; Frederick R Taylor; Debra Berkelhammer; Benjamen D Coats; Stephen Poole; Erin D Milligan; Steven F Maier; Jayson Rieger; Linda R Watkins
Journal:  J Neurosci       Date:  2009-11-04       Impact factor: 6.167

8.  Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.

Authors:  E M L Smith; H Pang; C Ye; C Cirrincione; S Fleishman; E D Paskett; T Ahles; L R Bressler; N Le-Lindqwister; C E Fadul; C Loprinzi; C L Shapiro
Journal:  Eur J Cancer Care (Engl)       Date:  2015-11-25       Impact factor: 2.520

9.  Systemic administration of an alpha-7 nicotinic acetylcholine agonist reverses neuropathic pain in male Sprague Dawley rats.

Authors:  Lisa C Loram; Frederick R Taylor; Keith A Strand; Steven F Maier; Jason D Speake; Kristen G Jordan; John W James; Steven P Wene; Robert C Pritchard; Heather Green; Katherine Van Dyke; Anatoly Mazarov; Sharon R Letchworth; Linda R Watkins
Journal:  J Pain       Date:  2012-12       Impact factor: 5.820

Review 10.  Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.

Authors:  Alec B O'Connor
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.